Literature DB >> 16272964

[Pulmonary complications of Behcet's disease and Takayasu's arteritis].

A Hamzaoui1, K Hamzaoui.   

Abstract

INTRODUCTION: Behçet's disease and Takayasu's arteritis are both forms of large vessel vasculitis involving autoreactive T cells active against HSP 60. STATE OF THE ART: Behçet's disease is more common than Takayasu's arteritis. Pulmonary aneurysms represent the major complication of pulmonary Behçet's disease and have a poor prognosis, being associated with massive haemoptysis. In situ pulmonary artery thrombus can lead to pulmonary infarction. Superior vena cava thrombosis progresses slowly, allowing the development of a prominent collateral circulation. Vascular inflammation can spread to the mediastinum, the pleura and the lungs with diffuse pulmonary haemorrhages, bronchiolitis and organising pneumonia. Electron beam tomodensitometry and MRI are the best diagnostic techniques for assessing pulmonary vascular lesions. In Takayasu's arteritis the pulmonary arteries are less frequently involved than the aorta. Pulmonary hypertension (PHT) and lung infarcts can complicate pulmonary arterial involvement and the association of malaise, fever and weight loss with PHT is characteristic of the disease. The diagnosis is confirmed by imaging means, particularly MRI, demonstrating parietal vascular inflammation.
CONCLUSION: Treatment of both conditions is based upon steroids and immunosuppression. Endovascular treatment may be used in a complementary way for aneurysms, arterial occlusion, and vena cava obstruction. However, patients often respond poorly to treatment and clinical trials using TNFalpha blockade, interferon alpha and vasodilators are in progress.

Entities:  

Mesh:

Year:  2005        PMID: 16272964     DOI: 10.1019/200530185

Source DB:  PubMed          Journal:  Rev Mal Respir        ISSN: 0761-8425            Impact factor:   0.622


  3 in total

1.  Release of B cell-activating factor of the TNF family in bronchoalveolar lavage from Behçet's disease with pulmonary involvement.

Authors:  Agnès Hamzaoui; Hanene Chelbi; Fayçal Hai Sassi; Kamel Hamzaoui
Journal:  Oxid Med Cell Longev       Date:  2010 Mar-Apr       Impact factor: 6.543

2.  NOD2 is highly expressed in Behçet disease with pulmonary manifestations.

Authors:  Kamel Hamzaoui; Hanadi Abid; Anissa Berraies; Jamel Ammar; Agnès Hamzaoui
Journal:  J Inflamm (Lond)       Date:  2012-02-13       Impact factor: 4.981

3.  Increased endothelin-1 levels of BAL fluid in patients with Behçet's disease.

Authors:  Kamel Hamzaoui; Hanene Chelbi; Mariam Kamoun; Imen Ben Dhifallah; Agnes Hamzaoui
Journal:  Mediators Inflamm       Date:  2007-03-19       Impact factor: 4.711

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.